Neurogene (NGNE) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic progress and clinical development

• NGN-401, a one-time gene therapy for Rett syndrome, is advancing through the Embolden registrational trial, with rapid enrollment and dosing of multiple participants in late 2025 following FDA alignment.

• Phase I/II data show durable, multi-domain functional improvements, with all pediatric participants gaining milestones, 35 developmental milestones gained, and 88% showing improved CGI-I scores, with no plateau observed up to 24 months post-treatment.

• The therapy uses the EXACT platform for precise transgene expression and is the only gene therapy designed to deliver full-length MECP2 protein to key brain and nervous system areas.

• Embolden trial design leverages learnings from Phase I/II, using a single-arm, open-label format with a composite primary endpoint and standardized, blinded video assessments; the primary endpoint is a responder-based composite at 12 months, requiring a 35% response rate for success.

• NGN-401 has been generally well tolerated, with most adverse events mild or moderate and consistent with known AAV gene therapy risks.

Market opportunity and commercialization plans

• Rett syndrome affects 15,000–20,000 patients in major markets, with no current disease-modifying therapies and high unmet need; the market is valued in the multi-billion-dollar range due to the lifelong care burden.

• NGN-401 is positioned as a one-time gene therapy with a premium price, supported by robust payer research and established reimbursement pathways; outpatient pathway options are being explored to simplify reimbursement and access.

• Commercial readiness includes converting trial sites to commercial centers, internal manufacturing scale-up, and ongoing market research to identify key adoption drivers, with rapid site conversion planned at launch.

• Lean commercial infrastructure is planned, leveraging relationships with Rett Centers of Excellence and focusing on smooth access for patients and caregivers.

• The company maintains a strong balance sheet, funding operations through Q1 2028, covering key milestones such as data readout, BLA submission, and pre-launch activities.

Industry landscape and future outlook

• The treatment landscape for Rett syndrome is evolving, with two potential gene therapies on the horizon and payers familiar with the disease and its burden.

• Efficacy and durability of functional improvements are expected to drive adoption, with room for multiple players in the market.

• Success in upcoming data releases will be measured by sustained, multi-domain improvements and reproducibility across patient cohorts.

• Early commercial activities and CMC performance qualification runs are underway, with further expansion and market education planned for 2026.

• Pipeline expansion is anticipated, with additional discovery programs progressing alongside NGN-401 commercialization efforts.